- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01204593
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)
Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen.
Primary Objective:
To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
Secondary Objectives:
To evaluate:
- The change of hemoglobin A1c (HbA1c) from baseline to week 12
- The percentage of patients with HbA1c < 7% at week 12 and week 24
- The FBG and the 7-point self monitoring of blood glucose (SMBG) at baseline, week 12 and week 24
- The daily dose for both insulin glulisine insulin glargine at baseline, week 12 and week 24
- The incidence of symptomatic hypoglycemias
- Adverse events
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
After a two-week run-in period patients will enter a six-month treatment period.
Estimated study duration per patient : 26 weeks (including a 2-week run-in period).
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Algeries, Algerije
- Investigational Site Number 01201
-
Algiers, Algerije
- Investigational Site Number 01202
-
Algiers, Algerije
- Investigational Site Number 01203
-
Algiers, Algerije
- Investigational Site Number 01204
-
-
-
-
-
Caba, Argentinië
- Investigational Site Number 03201
-
Caba, Argentinië
- Investigational Site Number 03202
-
Caba, Argentinië
- Investigational Site Number 03203
-
Caba, Argentinië
- Investigational Site Number 03204
-
Morón, Argentinië
- Investigational Site Number 03205
-
-
-
-
-
Curitiba, Brazilië, 80540-010
- Investigational Site Number 076-007
-
Distrito Federal, Brazilië, 71625-009
- Investigational Site Number 076-003
-
Fortaleza, Brazilië, 60430-370
- Investigational Site Number 076-010
-
Marília, Brazilië, 17519-101
- Investigational Site Number 076-006
-
Porto Alegre, Brazilië, 91350-250
- Investigational Site Number 076-004
-
São Paulo, Brazilië, 01244-030
- Investigational Site Number 076-002
-
-
-
-
-
Barranquilla, Colombia
- Investigational Site Number 17003
-
Bogotá, Colombia
- Investigational Site Number 17004
-
Bogotá, Colombia
- Investigational Site Number 17005
-
Bogotá, Colombia
- Investigational Site Number 17007
-
Medellin, Colombia
- Investigational Site Number 17006
-
-
-
-
-
Kuwait, Koeweit
- Investigational Site Number 01
-
-
-
-
-
Guadalajara, Mexico, 44600
- Investigational Site Number 48401
-
Guadalajara, Mexico, 44656
- Investigational Site Number 48402
-
Guadalajara, Mexico, 44680
- Investigational Site Number 48404
-
Monterrey, Mexico, 64460
- Investigational Site Number 48403
-
-
-
-
-
Riyadh, Saoedi-Arabië, 11415
- Investigational Site Number 1
-
-
-
-
-
Sfax, Tunesië
- Investigational Site Number 78805
-
Sfax, Tunesië
- Investigational Site Number 78801
-
Tunis, Tunesië
- Investigational Site Number 78802
-
Tunis, Tunesië, 1006
- Investigational Site Number 78803
-
Tunis, Tunesië
- Investigational Site Number 78804
-
-
-
-
-
Benoni, Zuid-Afrika
- Investigational Site Number 12468
-
Benoni, Zuid-Afrika
- Investigational Site Number 710004
-
Bloemfontein, Zuid-Afrika, 9301
- Investigational Site Number 12466
-
Bloemfontein, Zuid-Afrika, 9301
- Investigational Site Number 710006
-
Durban, Zuid-Afrika, 4091
- Investigational Site Number 710002
-
Durban, Zuid-Afrika, 4091
- Investigational Site Number 12464
-
Durban, Zuid-Afrika, 4091
- Investigational Site Number 12465
-
Durban, Zuid-Afrika, 4091
- Investigational Site Number 710001
-
Port Elizabeth, Zuid-Afrika, 6000
- Investigational Site Number 12484
-
Port Elizabeth, Zuid-Afrika, 6000
- Investigational Site Number 710003
-
Pretoria, Zuid-Afrika
- Investigational Site Number 12467
-
Pretoria, Zuid-Afrika
- Investigational Site Number 710005
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
Known Type 1 diabetic patients (male or female) treated with any type of insulin regimen, except:
- continuous subcutaneous insulin infusion (CSII, or pump), and
- patients already treated with insulin glargine
- Age: 18-60 years inclusive
- HbA1c: 8% - 10% assessed over the past 6 month
- At least 1 year of continuous insulin treatment
Willingness to accept, and ability to follow:
- a basal bolus regimen (glargine x1 and glulisine x3 per day),
- self-monitoring blood glucose (SMBG)
- a fixed meal plan, or CHO counting
- Signed informed consent obtained prior to any study procedure
Criteria for entry in the treatment period:
- HbA1c 8-10% assessed between week -2 and week 0
- Serum creatinine ≤135 micromol/L in men and ≤110 micromol/L in women
- Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) lower or equal to three times the upper limit of normal
- Pregnancy test negative if women of childbearing potential
Exclusion criteria:
- History of hypersensitivity to insulin glargine and/or insulin glulisine
- Pregnant, breast-feeding or women of childbearing potential not using efficient contraception
- Brittle diabetes
- Known impaired renal function defined as serum creatinine > 135 micromol/L in men and > 110 micromol/L in women at study entry
- Known impaired hepatic function defined as Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal at study entry
- Diabetes ketoacidosis
- History of drug or alcohol abuse
- Psychiatric or mental disease
- Inclusion in another study in the past 6 months or previous inclusion in this study
- Patient unable or unwilling to manage properly the basal bolus regimen
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Insulin glargine + insulin glulisine
Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L). Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL. |
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
Andere namen:
Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC))
Tijdsspanne: between baseline (week 0) and endpoint (week 24)
|
between baseline (week 0) and endpoint (week 24)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change of HbA1c
Tijdsspanne: from baseline to week 12
|
from baseline to week 12
|
Percentage of patients with HbA1c < 7%
Tijdsspanne: at week 12 and week 24
|
at week 12 and week 24
|
Fasting Blood Glucose (FBG)
Tijdsspanne: at baseline, week 12 and week 24
|
at baseline, week 12 and week 24
|
7-point Self Monitoring of Blood Glucose (SMBG)
Tijdsspanne: at baseline, week 12 and week 24 (to be performed the week preceding each visit on two consecutive days)
|
at baseline, week 12 and week 24 (to be performed the week preceding each visit on two consecutive days)
|
Daily dose for insulin glulisine
Tijdsspanne: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
Daily dose for insulin glargine
Tijdsspanne: At baseline, week 12 and week 24
|
At baseline, week 12 and week 24
|
Symptomatic hypoglycemias
Tijdsspanne: From baseline (week 0) to endpoint (week 24)
|
From baseline (week 0) to endpoint (week 24)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- LANTU_R_05033
- U1111-1116-3450 (Andere identificatie: WHO)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus, type 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetestype1 | Diabetes mellitus type 1 | Auto-immuun diabetes | Diabetes Mellitus, insulineafhankelijk | Jeugddiabetes | Diabetes, auto-immuunziekte | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | Diabetes Mellitus,... en andere voorwaardenVerenigde Staten
-
University of California, San FranciscoJuvenile Diabetes Research FoundationVoltooidDiabetes mellitus type 1 | Diabetes mellitus, type I | Insulineafhankelijke diabetes mellitus 1 | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMVerenigde Staten, Australië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
Capillary Biomedical, Inc.BeëindigdDiabetes type 1 | Diabetes mellitus type 1 | Diabetes mellitus, type I | Diabetes Mellitus, insulineafhankelijk, 1 | IDDMOostenrijk
-
Capillary Biomedical, Inc.VoltooidDiabetes mellitus, type 1 | Diabetes type 1 | Diabetes mellitus type 1 | Diabetes Mellitus, insulineafhankelijk, 1Australië
-
Spiden AGDCB Research AGWervingDiabetes mellitus type 1 | Diabetes mellitus type 1 met hypoglykemie | Diabetes mellitus type 1 met hyperglykemieZwitserland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...OnbekendDiabetes mellitus type 1 met hyperglykemie | Diabetes mellitus type 1 met hypoglykemiePolen
-
Hoffmann-La RocheRoche DiagnosticsVoltooidDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Duitsland
-
AstraZenecaVoltooidDiabetes mellitus type 2 | Diabetes mellitus type 1Verenigde Staten
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)VoltooidDiabetes mellitus type 1 | T1DM | T1D | Nieuwe diabetes mellitus type 1Verenigde Staten, Australië
Klinische onderzoeken op INSULIN GLARGINE
-
Universiti Sains MalaysiaVoltooid
-
Julphar Gulf Pharmaceutical IndustriesParexel; Profil Institut für Stoffwechselforschung GmbHVoltooid